AYTU BIOPHARMA, INC
For the period ended Dec 31, 2024. Filed Feb 12, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Dec 31, 2024 · Filed Feb 12, 2025
AYTU$1.81+1.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unaudited Consolidated Statements of Cash Flows
(in thousands)
| Six Months Ended | ||
|---|---|---|
| December 31, | ||
| 2024 | 2023 | |
| Cash flows from operating activities: | ||
| Net income (loss) | $2,262 | $(8,340) |
| Adjustments to reconcile net income (loss) to cash provided by (used in) operating activities: | ||
| Depreciation, amortization and accretion | 2,766 | 3,634 |
| Stock-based compensation expense | 324 | 1,432 |
| Derivative warrant liabilities (gain) loss | (5,896) | 6,484 |
| Amortization of debt discount and issuance costs | 55 | 302 |
| Inventory write-down | 95 | 51 |
| Other non-cash adjustments | (529) | (50) |
| Non-cash adjustments from discontinued operations | 254 | 1,176 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable, net | (1,794) | (1,566) |
| Inventories | 961 | (1,805) |
| Prepaid expenses and other current assets | (679) | (830) |
| Accounts payable | 1,329 | (3,062) |
| Accrued liabilities | 2,341 | (3,554) |
| Other operating assets and liabilities, net | 306 | 3,805 |
| Changes in operating assets and liabilities from discontinued operations | (80) | 1,977 |
| Net cash provided by (used in) operating activities | 1,715 | (346) |
| Cash flows from investing activities: | ||
| Cash received from sales of fixed assets | 668 | — |
| Cash payments for fixed asset purchases | (142) | — |
| Other investing activities | — | (250) |
| Net cash provided by (used in) investing activities | 526 | (250) |
| Cash flows from financing activities: | ||
| Proceeds from issuance of stock and warrants | — | 86 |
| Net proceeds received from (payments made on) revolving credit facility | 1,617 | (537) |
| Payment made to fixed payment arrangements | (2,537) | (2,204) |
| Payment of stock issuance costs | — | (160) |
| Payments made to borrowings | (929) | (45) |
| Net cash used in financing activities | (1,849) | (2,860) |
| Net change in cash and cash equivalents | 392 | (3,456) |
| Cash and cash equivalents at beginning of period | 20,006 | 22,985 |
| Cash and cash equivalents at end of period | $20,398 | $19,529 |
| Supplemental disclosure of cash flow information: | ||
| Cash paid for interest | $752 | $2,170 |
| Cash paid for income taxes | $1,419 | $432 |
| Non-cash investing and financing activities: | ||
| Other non-cash investing and financing activities | $483 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.